- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02330094
Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic in Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Have aneurysmal subarachnoid hemorrhage (aSAH) diagnosed by CT scan of the brain and/or angiogram evidence of intracranial aneurysm (CTA or digital subtraction angiogram or MRA)
- Have symptomatic headache
- Able to swallow and verbalize pain score
- No known allergy to gabapentin or fentanyl
- Numeric pain score ≥ 5
- Ability to provide written personal consent
Exclusion Criteria:
- Gabapentin use prior to SAH admission
- Renal failure with creatinine clearance less than 30 mL/min
- Unable to receive standard of care pain medications
- Pregnant or breastfeeding patients
- History of severe depression defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gabapentin
Gabapentin capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
|
Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance. Both groups will receive other standard of care pain medications.
Other Names:
|
Placebo Comparator: Control
Placebo capsules 100 mg ter in die (TID), 200 mg TID, 300 mg TID, 400 mg TID, 600 mg TID, 900 mg TID.
|
Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance. Both groups will receive other standard of care pain medications. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Numeric Pain Score
Time Frame: baseline through day 7
|
Pain was measured on a Visual Analogue Scale (VAS) rated from 0-10, where 0 was no pain and 10 was the worst pain imaginable.
The numeric pain score was measured every 4 hours and the total score over 24 hours was averaged as the daily numeric pain score.
The daily scores were then averaged over a 7 day period for a single average pain score.
|
baseline through day 7
|
Average Narcotic Consumption
Time Frame: baseline through day 7
|
The amount of narcotics administered, averaged over a 7 day period, calculated in total morphine equivalents (ME).
|
baseline through day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain Control Satisfaction Questionnaire
Time Frame: Day 8
|
The Brigham and Women's Hospital Management of Post-operative Pain Patients discharge questionnaire (BWQ) was used to measure pain control satisfaction.
The questionnaire was modified and transformed into a uniform scale so all numbers were on the same direction.
Subjects were asked to answer six questions on a score of 0-5, for a total possible range of 0-30.
A lower score indicated a better outcome (less pain) and higher pain control satisfaction and a higher score indicated a worse outcome (more pain) and lower pain control satisfaction.
|
Day 8
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: William Freeman, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Intracranial Hemorrhages
- Hemorrhage
- Headache
- Subarachnoid Hemorrhage
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
- 14-005288
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aneurysmal Subarachnoid Hemorrhage
-
Medical University InnsbruckRecruitingSubarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralAustria
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingSubarachnoid Hemorrhage, Aneurysmal | Subarachnoid Hemorrhage, SpontaneousItaly
-
El Instituto Nacional de Neurologia y Neurocirugia...CompletedBrain Ischemia | Subarachnoid Hemorrhage | Subarachnoid Hemorrhage, Aneurysmal | Delayed Cerebral Ischemia | Aneurysmal Subarachnoid Hemorrhage | Vasospasm, CerebralMexico
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; Azienda Ospedaliera... and other collaboratorsRecruitingSubarachnoid Hemorrhage, Aneurysmal | Poor Grade Subarachnoid HemorrhageItaly
-
Hackensack Meridian HealthRecruitingStroke | Subarachnoid Hemorrhage, Aneurysmal | Aneurysmal Subarachnoid Hemorrhage | Cerebral Aneurysm | Cerebral Ischemia | Vasospasm, CerebralUnited States
-
University of CalgaryUnknownIntraventricular Hemorrhage | Aneurysmal Subarachnoid HemorrhageCanada
-
Dr. Roman UllrichAustrian Science Fund (FWF)RecruitingSubarachnoid Hemorrhage, AneurysmalAustria
-
Unity Health TorontoWithdrawnSubarachnoid Hemorrhage, AneurysmalCanada
-
National Institute of Mental Health and Neuro Sciences...CompletedSubarachnoid Hemorrhage, AneurysmalIndia
-
Edge Therapeutics IncTerminatedSubarachnoid Hemorrhage, AneurysmalUnited States, Canada, Australia, Hong Kong, Israel, New Zealand, Singapore, Finland, Czechia, Austria, Germany
Clinical Trials on Gabapentin
-
University Hospital, GhentAmsterdam UMC, location VUmc; University GhentCompletedEpilepsy and Neuropathic PainBelgium
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
Mayo ClinicCompleted
-
Viatris Specialty LLCCompletedAbuse PotentialUnited States
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; Merck Pvt. Ltd, PakistanCompletedHealthy Volunteers | Bioequivalence StudyPakistan
-
Indiana UniversityCompletedPostoperative PainUnited States
-
Celgene CorporationCompletedBreast Neoplasms | Metastases, NeoplasmUnited States
-
Celgene CorporationCompletedNeoplasms | Metastases, NeoplasmUnited States
-
XenoPort, Inc.Completed
-
Endo PharmaceuticalsCompletedCarpal Tunnel Syndrome | Complex Regional Pain Syndrome | Peripheral Neuropathy | Diabetic Neuropathy | Postherpetic Neuralgia | HIV Neuropathy | Idiopathic Sensory NeuropathyUnited States